CoronaryAtlas logo
CoronaryAtlas
Platelet-derived growth factor
Pathway / Plaque inflammation

Platelet-derived growth factor

protein

PDGF released from activated platelets promotes plaque inflammation and fibrous-cap vulnerability.

Pathway placement
Cascade stepPlaque inflammation
Confidencemedium
RationalePlatelet α-granule product; drives plaque progression, vascular remodeling, and cap degradation.
Also acts inPlatelet activation, Cap degradation / rupture
Druggability
Not assessed (no mapped human gene target).

Type I vs non-Type I discrimination

ScoresShared / rises in both
R — rupture / Type-I
67
C — non-Type-I
58
A — assay feasibility
68
E — evidence strength
71
T1DI (composite)
26
Specificity differential (R−C)+8.7
Non-Type-I axis panel
Does this marker also move in each non-Type-I setting? mag 0–3; higher means less Type-I-specific. n/a = no evidence retrieved, which is not the same as no change.
2sepsis / systemic inflammationmag 2
2anemia / acute blood lossn/a
2hypovolemia / dehydrationmag 2
2tachyarrhythmiamag 2
2hypoxemia / respiratory failuren/a
2hypertensive emergencymag 2
2high-demand / peri-operative stressmag 1
3sudden cardiac deathn/a
4aPCI-related periproceduralmag 2
4bstent thrombosismag 1
4cin-stent restenosismag 2
5CABG-relatedn/a
Coverage: 8/12 axes with evidence
Tier: deep-scored (abstract-extracted) · 22 supporting references. See the discrimination table for all markers.

Assay & specimen

Class-level default (no specific cleared assay)— generic method inferred from analyte class; confirm against a specific product insert before use.
Specimen
Serum or plasma
Collection tube
Serum separator (gold/red-top, SST) · K2/K3-EDTA (lavender-top)
Method / principle
Sandwich immunoassay (ELISA) — research-grade unless a cleared assay exists
Reagent / substrate
Matched anti-target antibody pair (capture + labeled detection)
Platform
ELISA microplate or multiplex (Luminex/MSD)
Turnaround · availability
Send-out / research · Research-grade (no universal clinical assay)

Literature evidence(5)